The authors of a related comment note that epilepsy in Lennox-Gastaut syndrome is pharmacoresistant, and to date no single antiepileptic drug has been shown to be superior. After failure of first-line conventional antiepileptics, second-line therapies include rufinamide, clobazam, felbamate, and zonisamide, and non-pharmacological treatments.
They say that the participants in this study are representative of those likely to be seen in clinical practice. The results show a benefit of cannabidiol on seizure frequency, and together with those of previous studies indicate that it is efficacious in this indication. However it was a short-term study – longer-term efficacy and safety is currently being assessed in an open-label extension study.